French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland ...

Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, today announced ...

CNW/ - DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI" or "the Trust") today announced its financial results for the ...

We will begin the MacroGenics 2024 third-quarter corporate progress and financial results conference call in just a moment.

Scott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, ...

Pero hay un inconveniente. En sus primeras etapas, la diabetes no causa síntomas, pero el medicamento, comercializado como Tzield, solo es efectivo durante esta fase silenciosa. Esta es la ...

Net income for the quarter ended September 30, 2023, included a $50 million milestone payment from Sanofi related to the previously disclosed achievement of a primary endpoint in a TZIELD clinical ...

Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment ...

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks that TZIELD, vobramitamab duocarmazine ...

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks that TZIELD, vobramitamab duocarmazine ...